| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Zhan,Yong-Ning | Chairman | 2.36% | |
| Vacancy | Director | ||
| Gao,An-Min | Director | 0.00% | |
| Gao,Jian-Xun | Director | 1.20% | |
| Cai,Shi-Chen | Director | 2.83% | CI MEI ASSET MANAGEMENT CO., LTD. |
| Li,Zheng-Xing | Director | 1.94% | NANF ANGCAO BIOLOGICAL TECHNOLOGY CORPORATION |
| Yang,Yong-Cheng | Independent Director | 0.00% | |
| Chen,Guan-Zhi | Independent Director | 0.00% | |
| Vacancy | Independent Director |
Change Company Name to TIANMING PHARMACEUTICAL CO., LTD. (FORMER NAME: ZHONGSHAN PHARMACEUTICAL CO., LTD.)
2022/07/04
Change Company Name to TIMING PHARMACEUTICAL CO., LTD.
2022/07/04
Change Person in Charge to Zhan,Yong-Ning
2022/07/04
Change Person in Charge to Zhan,Yi-Zhen
2022/04/18
Change Capital to 1,000,000,000
2013/06/26
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | 598,294 | 1,332,788 | 1,135,172 |
| Operating cost | 377,287 | 915,532 | 755,455 |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | 221,007 | 417,256 | 379,717 |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | 221,007 | 417,256 | 379,717 |
| Operating expenses | 190,102 | 345,092 | 323,427 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | 30,905 | 72,164 | 56,290 |
| Non-operating income and expenses | -1,238 | -30,077 | -18,430 |
| Net profit (loss) before tax | 29,667 | 42,087 | 37,860 |
| Income tax expense (benefits) | -1,574 | 1,308 | 928 |
| Net profit (loss) of ongoing business for the current period | 31,241 | 40,779 | 36,932 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | 31,241 | 40,779 | 36,932 |
| Other comprehensive profit (loss), net | 15,891 | -10,930 | 8,820 |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | 47,132 | 29,849 | 45,752 |
| Net profit (loss) attributable to owners of parent company | 37,096 | 50,196 | 55,340 |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | -5,855 | -9,417 | -18,408 |
| Comprehensive profit (loss) attributable to owners of parent company | 45,464 | 44,440 | 59,918 |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | 1,668 | -14,591 | -14,166 |
| Basic earnings per share (yuan) | 0 | 0 | 0 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | 40,086 | 201,096 | 157,571 |
| Net cash inflows (outflows) from investing activities | -33,819 | -94,325 | -73,855 |
| Net cash inflow (outflow) from financing activities | -3,761 | 4,765 | 10,746 |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | 7,499 | -3,278 | -4,859 |
| Increase (decrease) in cash and cash equivalents in the current period | 10,005 | 108,258 | 89,603 |
| Beginning balance of cash and cash equivalents | 388,512 | 280,254 | 190,651 |
| Ending balance of cash and cash equivalents | 398,517 | 388,512 | 280,254 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 1,241,358 | 1,194,620 | 1,016,014 |
| Non-current asset | 1,659,572 | 1,664,210 | 1,631,553 |
| Total asset | 2,900,930 | 2,858,830 | 2,647,567 |
| Current liability | 1,127,182 | 1,091,024 | 890,588 |
| Non-current liability | 409,749 | 421,680 | 423,848 |
| Total liability | 1,536,931 | 1,512,704 | 1,314,436 |
| share capital | 858,830 | 858,830 | 858,830 |
| Equity - secruity token | - | - | - |
| capital reserve | 74,991 | 73,232 | 71,249 |
| retained earning | 92,043 | 89,299 | 56,280 |
| Other equity | 7,143 | -1,225 | 4,531 |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | 1,033,007 | 1,020,136 | 990,890 |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | 330,992 | 325,990 | 342,241 |
| Total Equity | 1,363,999 | 1,346,126 | 1,333,131 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 12 | 11 | 11 |
Pay the ticket
2010
Fulfill contract
2023
Pay severance pay
2018, 2019, 2021
Petition for trial
2011
Pay severance pay, etc.
2021
Appointment of inspector
2020
Tort damages compensation, etc.
2011
Petition for determination of legal expenses
2013
Revocation of resolutions of shareholders' meeting
2020
Confirmation of the existence of employment relationship
2024
Infringement of copyright related property rights disputes, etc.
2011
Others
2020
Payment order
2018, 2020
Pay the ticket
2019, 2020, 2021
Fulfill contract
2023
Pay for the goods
2020
Invalidating Judgment
2013
Promissory note ruling
2020, 2021
Appointment of inspector
2021
Damage to reputation, etc.
2020
Pay for liquidated damages
2024
Compensation for damage, etc.
2024
Debt default compensation, etc
2014, 2015
Petition filed for public summons
2012
Revocation of resolutions of shareholders' meeting
2021, 2022
Infringement of copyright related property rights disputes, etc.
2012, 2013
